HOUSTON — Houston has drilled for oil, launched astronauts, built the world’s largest medical complex and helped redefine American energy. Now the Bayou City is adding another economic engine to its résumé: manufacturing medicines that could reach patients around the world.

Eli Lilly and Company officially broke ground September 21 on its massive $6.5 billion pharmaceutical manufacturing campus at Generation Park in northeast Houston, launching one of the most consequential life-sciences manufacturing projects in Texas history. The active pharmaceutical ingredient facility is expected to create approximately 4,000 construction jobs and more than 600 permanent high-wage positions.

And among the Houston-area leaders helping mark the milestone was Harris County Precinct 1 Commissioner Rodney Ellis.

Generation Park is located within Harris County Precinct 1, making the development especially significant to Ellis and the communities his office represents. Ellis joined Gov. Greg Abbott, Lilly Chairman and CEO Dave Ricks, Lilly Houston Site Head Diane Tennenhouse, San Jacinto College Chancellor Dr. Brenda Hellyer and other community leaders at the groundbreaking.

Ellis’ involvement stretches back to Lilly’s original Houston announcement in September 2025, when he joined state and local officials welcoming the company to Harris County.

At the time, Ellis called Lilly’s decision “a powerful testament to the strength of our community,” emphasizing the potential for living-wage employment, workforce development and broader economic opportunity. He also pointed to the combination of Generation Park infrastructure, San Jacinto College workforce training and the region’s labor pool as important ingredients in Houston’s emerging life-sciences ecosystem.

Now, shovels are officially in the ground.

The 236-acre campus will manufacture active pharmaceutical ingredients for medicines including Foundayo (orforglipron), Lilly’s first synthetic oral GLP-1 medication. The FDA approved Foundayo on April 1, 2026, for long-term weight reduction in qualifying adults with obesity or overweight when used with diet and physical activity. Unlike the injectable medicines that helped ignite the GLP-1 revolution, Foundayo is taken as a daily tablet.

But Lilly’s Houston ambitions go considerably beyond one medication.

The company says the facility will support production of small-molecule medicines and advanced therapeutics spanning cardiometabolic health, oncology, immunology and neuroscience, while strengthening domestic pharmaceutical manufacturing and supply chains.

Then comes perhaps the most Houston-style part of the story: training people for the jobs before the doors even open.

Lilly announced $12.5 million for San Jacinto College to expand workforce training, facilities and equipment supporting advanced chemical synthesis manufacturing. Another $2.5 million will support scholarships through the San Jacinto College Foundation.

For Houston, the Lilly groundbreaking represents more than concrete, laboratories and corporate investment. It connects the region’s historic strengths in medicine, engineering, education and advanced manufacturing.

Houston will always be Space City, an Energy Capital and home to a world-renowned medical community.

Now, with billions flowing into Generation Park, Houston is increasingly making another case for itself:

The medicines of tomorrow can be made right here at home.

 

Eli Lilly Information

Eli Lilly